Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEAN
The agreement combines upfront and potential milestone payments with royalties and a 50% share of regional gross profits.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ocugen (OCGN) granted Celairis Therapeutics exclusive commercialization rights to OCU400 in Australia, New Zealand and Association of Southeast Asian Nations markets.
The agreement provides for an upfront fee and potential development and milestone payments totaling up to $7.1 million, including $6.1 million associated with the upfront payment and top-line results. Ocugen also receives a high single-digit percentage royalty on net sales and 50% of gross profits from regional OCU400 net sales. Celairis handles regional regulatory submissions, market access and commercialization. The parties expect a supply agreement under which Ocugen would manufacture and supply OCU400.
Ocugen expects Phase 3 results for the investigational retinitis pigmentosa therapy in Q1 2027, followed by planned U.S. and European regulatory submissions; regional submissions are expected afterward.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointExclusive Celairis license establishes an OCU400 commercialization partnership covering Australia, New Zealand and ASEAN markets.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Upfront fee and potential development and milestone payments total up to $7.1 million. 2.2% of market cap
- Minor point. Forward-looking: it has not happened yet and may not happen.High single-digit percentage royalty gives Ocugen participation in regional OCU400 net sales.
- Minor point. Forward-looking: it has not happened yet and may not happen.50% of gross profits from regional OCU400 net sales goes to Ocugen.
- Minor point. Forward-looking: it has not happened yet and may not happen.Celairis assumes responsibility for regional regulatory submissions, market access and commercialization.
2 minor points
- Minor point. Forward-looking: it has not happened yet and may not happen.Phase 3 top-line results are expected in the first quarter of 2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.Global regulatory submissions are planned after results, including U.S. and European applications.
Negative
- Moderate pointManufacturing and supply agreement remains an expected future agreement between Ocugen and Celairis.
- Minor point$6.1 million is associated with both the upfront payment and top-line results, rather than solely upfront cash.
- Minor point. Forward-looking: it has not happened yet and may not happen.Regional regulatory submissions are expected to follow the planned U.S. and European submissions.
News Explained
The license is executed, but OCU400 remains investigational, unapproved and unavailable for supply in the territory, so execution has not changed its current supply status.
Key Figures
- Potential development and milestone payments
- Up to $7.1 million
- License agreement
- Payment component
- $6.1 million
- Associated with the upfront payment and OCU400 top-line results
- Royalty
- High single-digit percentage
- On net sales in the Territory
- Share of gross profits
- 50%
- From OCU400 net sales in the Territory
- OCU400 topline data timing
- First quarter of 2027
- Phase 3 liMeliGhT trial
- Regional population
- 725 million people
- Estimated population across the region
Historical Context
-
Ocugen granted Roots exclusive OCU400 rights in MENA for upfront, milestone, and royalty consideration.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
retinitis pigmentosa medical
biologics license application regulatory
marketing authorization application regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Celairis receives exclusive rights to commercialize OCU400, Ocugen's investigational modifier gene therapy for retinitis pigmentosa (RP), in Australia, New Zealand, and member states of the Association of Southeast Asian Nations (ASEAN) markets
- Expands access to a potential one-time treatment gene therapy for RP across a region with an estimated 725 million people, following potential OCU400 approval in the U.S.
- Ocugen receives an upfront license fee, potential development and milestone payments totaling up to
$7.1 million , including$6.1 million associated with the upfront payment and OCU400 top-line results (expected in the first quarter of 2027), a high single-digit percentage royalty on net sales, and50% of gross profits from OCU400 net sales across the region
- Celairis will be responsible for regional regulatory submissions, market access, and commercialization of OCU400 across the region
MALVERN, Pa. and SYDNEY, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, and Celairis Therapeutics Holdings Pty Ltd. ("Celairis"), a Sydney-based in-licensing, development, and commercialization biopharmaceutical company focused on Australia, New Zealand, Taiwan, and ASEAN, today announced the execution of an exclusive license agreement (the "License Agreement") granting Celairis an exclusive license to commercialize OCU400, Ocugen's investigational modifier gene therapy for the treatment of RP, in Australia, New Zealand, and ASEAN markets (the "Territory").
Under the terms of the License Agreement, Ocugen will receive an upfront license fee, as well as potential development and milestone payments totaling up to
"Australia, New Zealand, and ASEAN are large, diverse and complex markets, and establishing a partnership with a regional company like Celairis and its strong local network is critical to our goal of global patient access," said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen. "This agreement marks our third strategic regional partnership for OCU400, underscoring the growing momentum behind our global access strategy and bringing our potential one-time treatment gene therapy closer to patients around the world."
OCU400 is an investigational therapy for RP, a group of inherited retinal diseases that cause progressive vision loss, and in many cases, blindness. OCU400 has not been approved or registered and is not available for supply in any markets of the Territory. Ocugen is conducting the Phase 3 liMeliGhT clinical trial of OCU400, with topline data expected in the first quarter of 2027, followed by planned global regulatory submissions, including a Biologics License Application in the U.S. and a Marketing Authorization Application in Europe. Regulatory submissions in the Territory are expected to follow.
"Ocugen is the kind of partner Celairis was built for: a late-stage program, a clear strategy for reaching patients globally, and a conviction we share that geography should not decide access to new medicines," said Matt Zeller, Chief Executive Officer, Co-Founder, and Managing Director of Celairis. "Celairis brings the development, regulatory, and market access capability to do that across our region, and we look forward to building the relationship with Ocugen."
About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology company developing gene therapies for blindness diseases. The Company's breakthrough modifier gene therapy platform has the potential to address significant unmet medical needs across large patient populations through a gene-agnostic approach. Unlike traditional gene therapies and gene-editing technologies that target a single gene mutation, Ocugen's modifier gene therapies are designed to address the underlying disease biology by restoring balance across multiple gene networks. The Company is currently advancing programs for inherited retinal diseases and other causes of blindness that affect millions worldwide, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, an advanced form of dry age-related macular degeneration. Discover more at www.ocugen.com and follow the Company on LinkedIn and X.
About Celairis Therapeutics
Celairis Therapeutics is an in-licensing, development, and commercialization biopharmaceutical company unlocking broad and equitable access to advanced therapies for patients across 14 markets in Australia, New Zealand, Taiwan, and ASEAN. Celairis secures regional rights to medicines in oncology and hematology, specialty conditions, and rare diseases, then runs clinical development, regulatory approval, market access, supply chain, and commercial launch on one end-to-end platform. Founded in 2026, Celairis is headquartered in Sydney, Australia. For more information, visit www.celairis.com and follow Celairis on LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the anticipated benefits to Ocugen of the license agreement and planned supply agreement with Celairis, as well as statements regarding strategy, the potential amounts of milestone payments and profit share payments that may be received under the license agreement, including Ocugen’s obligations under its prior license and commercialization agreements, the timing of regulatory submissions and the potential availability of OCU400 in the Territory, business plans and objectives for Ocugen's clinical programs, plans and timelines for the preclinical and clinical development of Ocugen's product candidates, including the therapeutic potential, clinical benefits and safety thereof, expectations regarding timing, success and data announcements of current ongoing preclinical and clinical trials, including the timing of data readouts and marketing applications, the ability to initiate new clinical programs, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, statements regarding potential market size and commercial possibilities of Ocugen's product candidates, which are subject to risks and uncertainties. Ocugen may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from Ocugen's current expectations, including, but not limited to, the risks that the license agreement and planned supply agreement with Celairis will not lead to the current anticipated benefits to Ocugen; that the supply agreement with Celairis will not be entered into; that OCU400 may not receive regulatory approval in any jurisdiction, including in the Territory; that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing may not be predictive of the results or success of later clinical trials; and that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in Ocugen's filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled "Risk Factors" in the quarterly and annual reports that Ocugen files with the SEC. Any forward-looking statements that Ocugen makes in this press release speak only as of the date of this press release. Except as required by law, Ocugen assumes no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Contacts
Ocugen
Investors: Candice Masse, astr partners, candice.masse@astrpartners.com
Media: Chris Clark, Ocugen, chris.clark@ocugen.com
Celairis Therapeutics
Media: media@celairis.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What payments will Ocugen receive under the Celairis OCU400 license agreement?
Ocugen will receive an upfront fee and potential development and milestone payments totaling up to $7.1 million, plus a high single-digit percentage royalty on net sales and 50% of gross profits from regional OCU400 net sales. The payment package includes $6.1 million associated with the upfront payment and top-line results.
When does Ocugen expect OCU400 Phase 3 results and regulatory submissions?
Ocugen expects top-line results from the Phase 3 liMeliGhT trial in the first quarter of 2027. Planned global submissions afterward include a U.S. Biologics License Application and a European Marketing Authorization Application. Submissions in Australia, New Zealand and ASEAN markets are expected to follow.